BioSpace News Archive

WAKIX ® (pitolisant) Total Revenue of $160 Million for Full-Year 2020 ; $56 Million for Fourth Quarter 2020 Clinical Utility of WAKIX was Expanded with Additional Approval for Treatment of Cataplexy in Adults with Narcolepsy Enrollment Continues in Phase 2 Trial of Patients with Prader-Willi Syndrome On Track to Initiate Two Additional Clinical Trials with Pitolisant in 2021 Conference Call and Webcast to be Held Today at 8:30 a.m. ET

– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 – Strong balance sheet enables significant optionality for growth and accelerated advancement of pipeline programs

A single dose of the Pfizer-BioNTech COVID-19 vaccine produces a much weaker antibody response in long-term care residents than it does in younger healthy adults, new research has found.

-Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) by year-end -

Novari Health has announced that it has executed an agreement with Thunder Bay Regional Health Sciences Centre (TBRHSC) to implement its medical imaging referral management software technology.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2020.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21), which takes place virtually April 6-10, 2021 .

Innovative qPCR platform simplifies molecular diagnostic workflows for infectious disease, oncology and COVID-19 testing

First Patient Enrolls in FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA ® (pegloticase injection) and Methotrexate to Treat Uncontrolled Gout -- New Clinical Trial Complements Ongoing Efforts to Evolve the Patient Experience with KRYSTEXXA --

Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present a trial-in-progress poster on KD033-101, the Companys ongoing dose-escalation, dose-expansion trial of KD033 in patients with metastatic and locally advanced solid tumors, at the 2021 American Association for Cancer Research (AACR) Annual Meeting, taking place virtually April 10 - 15, 2021.